隆云;郭清华;刘大为;张小江;宋连燕;何怀武;
LONG Yun;GUO Qing-hua;LIU Da-wei;ZHANG Xiao-jiang;SONG Lian-yan;HE Huai-wu;Intensive Care Unit,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;Intensive Care Unit,Daxing Hospital,Capital Medical University;Clinical Laboratory,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;Intensive Care Unit,Beijing Shunyi Hospital;

• 1:中国医学科学院 北京协和医学院 北京协和医院重症医学科
• 2:首都医科大学大兴医院重症监护病房
• 3:中国医学科学院 北京协和医学院 北京协和医院检验科
• 4:北京顺义区医院重症医学科

摘要(Abstract)：

目的比较泛耐药鲍曼不动杆菌(pan-drug resistant Acinetobacter baumannii,PDRAB)菌血症与非泛耐药鲍曼不动杆菌(non-pan-drug resistant Acinetobacter baumannii,NPDRAB)菌血症的临床资料,探讨PDRAB菌血症的危险因素及其临床结局。方法本研究为回顾性队列研究,纳入对象为2010年1月1日至2012年12月31日就诊于北京协和医院的鲍曼不动杆菌菌血症患者,采用统一的标准表格收集患者的临床资料和检验结果,以鲍曼不动杆菌血培养标本采集14 d内发生院内死亡为主要临床结局。结果共纳入52例鲍曼不动杆菌菌血症患者,平均年龄(54±20)岁,其中男性30例(57.7%);平均急性生理与慢性健康状况Ⅱ(acute physiology and chronic health evaluationⅡ,APACHEⅡ)评分(21±9)分,平均序贯器官衰竭评估(sepsis-related organ failure assessment,SOFA)评分(10±5)分;鲍曼不动杆菌菌血症发生前,患者中位住院时间为12 d(7~20 d);仅6例患者对碳青霉烯类药物敏感。33例患者感染NPDRAB,19例感染PDRAB。在感染鲍曼不动杆菌前,PDRAB患者与NPDRAB患者比较,接受机械通气概率更大(94.7%比63.6%,P=0.031),住院时间更长(中位住院时间17 d比10 d,P=0.025)。鲍曼不动杆菌菌血症患者14 d死亡率为67.3%(35/52)。多因素分析提示,脓毒性急性肾损伤(OR 7.9,95%CI 1.113~55.448,P=0.039)、不适当抗菌药物治疗(OR 9.4,95%CI 1.020~87.334,P=0.048)和降钙素原水平(OR 1.3,95%CI 1.332~1.088,P=0.005)是鲍曼不动杆菌菌血症患者14 d死亡的独立危险因素。结论鲍曼不动杆菌具有多重耐药性,甚至对目前所有全身用抗菌药物均不敏感,感染患者死亡率较高。菌血症发生前接受机械通气和住院时间是PDRAB菌血症的危险因素,但PDRAB感染本身不能作为判断患者预后不良的指标。不适当抗菌药物治疗、脓毒性急性肾损伤和降钙素原水平是鲍曼不动杆菌菌血症患者14 d死亡的独立危险因素。
Objective To determine the risk factors and outcomes of pan-drug resistant Acinetobacter baumannii( PDRAB) bacteremia by comparing clinical data of PDRAB patients with those of non-pan-drug resistant Acinetobacter baumannii( NPDRAB) bacteremia. Methods This retrospective cohort study included patientswith Acinetobacter baumannii bacteremia diagnosed and treated in Peking Union Medical College Hospital during January 1,2010 and December 31,2012. Clinical data and laboratory test results of the patients were collected with unified forms. The primary clinical outcome was in-hospital death within 14 days after sample collection for blood culture of Acinetobacter baumannii. Results A total of 52 patients with Acinetobacter baumannii bacteremia were included,with the mean age of 54 ± 20 years and including 30( 57. 7%) males. The mean acute physiology and chronic health evaluation Ⅱ( APACHE Ⅱ) score and sepsis-related organ failure assessment( SOFA)score were 21 ± 9 and 10 ± 5,respectively. The median length of hospital stay before Acinetobacter baumannii bacteremia was 12 days( 7- 20 days). Among these patients,only 6 cases were sensitive to carbapenem. Thirtythree cases were infected by NPDRAB and 19 by PDRAB. Compared with NPDRAB patients,PDRAB patients had a higher rate of receiving mechanical ventilation( 94. 7% vs. 63. 6%,P = 0. 031) and a longer hospital stay( median: 17 days vs. 10 days,P = 0. 025) before Acinetobacter baumannii infection. The 14-day mortality rate in patients with Acinetobacter baumannii bacteremia was 67. 3%( 35 /52). In multivariate analysis,septic acute kidney injury [odds ratio( OR) 7. 9,95% confidence interval( CI) 1. 113- 55. 448,P = 0. 039],inappropriate anti-microbial therapy( OR 9. 4,95% CI 1. 020- 87. 334,P = 0. 048),and procalcitonin level( OR 1. 3,95% CI 1. 332- 1. 088,P = 0. 005) were independent risk factors of 14-day mortality in Acinetobacter baumannii bacteremia patients. Conclusions Acinetobacter baumannii has multi-drug resistance and is even not susceptible to all currently available systemic antimicrobials. Acinetobacter baumannii infection is associated with high mortality rate. Mechanical ventilation and long hospital stay before occurrence of bacteremia are risk factors for PDRAB bacteremia. However,PDRAB infection itself is not a predictor of poor prognosis. Inappropriate antimicrobial therapy,septic acute kidney injury,and procalcitonin level are independent risk factors of 14-day mortality in Acinetobacter baumannii bacteremia.

关键词(KeyWords)： 鲍曼不动杆菌;菌血症;危险因素;多重耐药性;不适当抗菌药物治疗
Acinetobacter baumannii;bacteremia;risk factor;multi-drug resistance;inappropriate antimicrobial therapy

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 隆云;郭清华;刘大为;张小江;宋连燕;何怀武;
LONG Yun;GUO Qing-hua;LIU Da-wei;ZHANG Xiao-jiang;SONG Lian-yan;HE Huai-wu;Intensive Care Unit,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;Intensive Care Unit,Daxing Hospital,Capital Medical University;Clinical Laboratory,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;Intensive Care Unit,Beijing Shunyi Hospital;

Email:

DOI:

参考文献(References)：

• [1]Garner JS,Jarvis WR,Emori TG,et al.CDC definitions for nosocomial infecions,1998[J].Am J Infect Control,1988,16:128-140.
• [2]Maragakis LL,Perl TM.Acinetobacter baumannii:epidemiology,antimicrobial resistance,and treatment options[J].Clin Infect Dis,2008,46:1254-1263.
• [3]Cisneros JM,Reyes MJ,Pachón J,et al.Bacteremia due to Acinetobacter baumannii:epidemiology,clinical and prognostic features[J].Clin Infect Dis,1996,22:1026-1032.
• [4]Munoz-Price LS,Weinstein RA.Acinetobacter infection[J].N Engl J Med,2008,358:1271-1281.
• [5]Peleg AY,Seifert H,Paterson DL.Acinetobacter baumannii:emergence of a successful pathogen[J].Clin Microbiol Rev,2008,21:538-582.
• [6]Gulen TA,Guner R,Celikbilek N,et al.Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant Acinetobacter baumannii[J/OL].Int J Infect Dis,(2015-06-27).doi:http://dx.doi.org/10.1016/j.ijid.2015.06.014.http://www.ijidonline.com/article/S1201-9712(15)00148-4/pdf.
• [7]Bruhn KW,Pantapalangkoor P,Nielsen T,et al.Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia[J].J Infect Dis,2015,211:1296-1305.
• [8]Robenshtok E,Paul M,Leibovici L,et al.The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia:risk factors and outcomes[J].J Hosp Infect,2006,64:282-287.
• [9]Knaus WA,Draper EA,Wagner DP,et al.APACHEⅡ:a severity of disease classification system[J].Crit Care Med,1985,13:818-829.
• [10]Vincent JL,Moreno R,Takala J,et al.The SOFA(Sepsisrelated Organ Failure Assessment)score to describe organ dysfunction/failure[J].Intensive Care Med,1996,22:707-710.
• [11]Falagas ME,Koletsi PK,Bliziotis IA.The diversity of definitions of multidrug-resistant(MDR)and pandrug-resistant(PDR)Acinetobacter baumannii and Pseudomonas aeruginosa[J].J Med Microbio,2006,55:1619-1629.
• [12]Mehta RL,Kellum JA,Shah SV,et al.Acute Kidney Injury Network:report of an initiative to improve outcomes in acute kidney injury[J].Crit Care,2007,11:R31.
• [13]Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference[J].Crit Care Med,2003,31:1250-1256.
• [14]Liu CP,Shih SC,Wang NY,et al.Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia[J/OL].J Microbiol Immunol Infect,(2014-12-30).doi:10.1016/j.jmii.2014.10.006.http://www.ejmii.com/article/S1684-1182(14)00233-3/fulltext.
• [15]Lee HY,Chen CL,Wu SR,et al.Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients[J].Crit Care Med,2014 42:1081-1088.
• [16]Jang TN,Lee SH,Huang CH,et al.Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit:a case-control study[J].J Hosp Infect,2009,73:143-150.
• [17]Kwon KT,Oh WS,Song JH,et al.Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia[J].J Antimicrob Chemother,2007,59:525-530.
• [18]Erbay A,I·dil A,Gzel MG,et al.Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections[J].Int J Antimicrob Agents,2009,34:575-579.
• [19]Tseng YC,Wang JT,Wu FL,et al.Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii[J].Diagn Microbiol Infect Dis,2007,59:181-190.
• [20]Routsi C,Pratikaki M,Platsouka E,et al.Carbapenem-resistant versus carbape-nem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit:risk factors,clinical features and outcomes[J].Infection,2010,38:173-180.
• [21]Choi JY,Park YS,Kim CO,et al.Mortality risk factors of Acinetobacter baumannii bacteremia[J].Intern Med J,2005,35:599-603.
• [22]Sakran JV,Michetti CP,Sheridan MJ,et al.The utility of procalcitonin in critically ill trauma patients[J].J Trauma Acute Care Surg,2012,73:413-418.
• [23]Georgopoulou AP,Savva A,Giamarellos-Bourboulis EJ,et al.Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis[J].J Crit Care,2011,26:331e1-e7.
• [24]Chertow GM,Burdick E,Honour M,et al.Acute kidney injury mortality,length of stay,and costs in hospitalized patients[J].J Am Soc Nephrol,2005,16:3365-3370.
• [25]Parmar A,Langenberg C,Wan L,et al.Epidemiology of septic acute kidney injury[J].Curr Drug Targets,2009,10:1169-1178.
• [26]Hamzic-Mehmedbasic A,Rasic S,Rebic D,et al.Renal function outcome prognosis in septic and non-septic acute kidney injury patients[J].Med Arch,2015,69:77-80.